Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
Key Highlights
- ➤Brepocitinib 45 mg delivered 69.2% clear or almost-clear skin versus 0% placebo
- ➤Brepocitinib 45 mg produced 22.3-point CSAMI-A reduction versus 0.7 points placebo
- ➤Brepocitinib 45 mg improved Skindex-16 by 23.5 points versus 8.9-point worsening placebo
- ➤BEACON+ Phase 3 topline data expected in calendar year 2028
- ➤BEACON+ enrolling approximately 140 patients across approximately 70 global sites
Expert Statements
Misha Rosenbach, Professor of Dermatology and Rheumatology and Director of the Cutaneous Sarcoidosis Program at the Hospital of the University of Pennsylvania
“Cutaneous sarcoidosis is often on the face and severely impacts patients, and there are no approved treatments.”
Misha Rosenbach, Professor of Dermatology and Rheumatology and Director of the Cutaneous Sarcoidosis Program at the Hospital of the University of Pennsylvania
“This is the largest study in skin sarcoidosis to date, and the result were striking – seeing clear or almost clear skin in more than two-thirds of patients on brepocitinib demonstrates dramatic improvement and was backed by multiple metrics showing this improved patients’ symptoms and quality of life.”
Misha Rosenbach, Professor of Dermatology and Rheumatology and Director of the Cutaneous Sarcoidosis Program at the Hospital of the University of Pennsylvania
“These published findings bring rigorous clinical evidence to a historically neglected disease and patient population and offer a compelling reason to believe that a fundamentally different future with more targeted, effective treatments may be possible for our patients.”
* At Week 16, 69% of participants receiving brepocitinib 45 mg achieved "Clear" or "Almost Clear" skin, with at least a 2-category improvement, compared with 0% receiving placebo * Improvements in skin disease activity were evident as early as Week 4, increased over time, and were accompanied by benefits on skin-related quality of life * Brepocitinib was well tolerated during the 16-week study period, with no serious adverse events (SAEs) * Findings support ongoing Phase 3 BEACON+ study in cutaneous sarcoidosis; topline data expected in calendar year 2028 * Results of the study will be shared by Dr. Misha Rosenbach, MD, in an oral presentation at ACR Convergence 2026 today, November 10 DURHAM, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized, double-blind, placebo-controlled trial evaluating oral brepocitinib in adults with cutaneous sarcoidosis (CS). The publication describes improvements in skin disease activity and skin-related quality of life over 16 weeks of treatment, with 69.2% of participants receiving brepocitinib 45 mg once daily achieving “Clear” or “Almost Clear” skin with at least a 2-category improvement, compared with none of the participants receiving placebo (P = 0.0047).
Get started
Create a free account to read the full story.